Active, not recruitingPhase 2NCT06775041
Study to Determine Optimal Dose and Evaluate Safety, Tolerability, and Pharmacokinetics of Progerinin in Patients With Hutchinson-Gilford Progeria Syndrome (HGPS)
Studying Hutchinson-Gilford progeria syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- PRG Science & Technology Co., Ltd.
- Intervention
- Progerinin(drug)
- Enrollment
- 10 enrolled
- Eligibility
- 1 years · All sexes
- Timeline
- 2025 – 2026
Study locations (1)
- Boston Children's Hospital, Boston, Massachusetts, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06775041 on ClinicalTrials.gov